Table 3.
The representative MTKIs nanoparticles for anti-tumor combination therapy.
| Nanoparticles | Combination Therapy | Cell Lines | Cell Viability Rate (%) | Treatment Conditions | Method | Ref. |
|---|---|---|---|---|---|---|
| Anlotinib@IR820 | PTT | MCF7 | 33 | 24 h([Anlotinib] = 0.8 ppm, [IR820] = 5 ppm, 808 nm, 0.8 W cm−2, 3min) | CCK8 | [87] |
| Lip-IR780-Sunitinib | PTT | 4T1 | 50 | 24 h([IR780] = 0.2 μg/mL, 808 nm, 1 W cm−2, 4min) | MTT | [29] |
| MoS2-PEG-Er/DOX | PTT | A549 | 6.1 | 24 h([MoS2-PEG] = 180 μg/mL,[Erlotinib] = 10 μg/mL, [DOX] = 20 μg/mL, 808 nm, 1 W cm−2, 10min) | MTT | [182] |
| HPGBCA | PDT | A549 | 50 | 48 h([HPGBCA] = 0.41 mM, 660 nm, 50 mW cm−2, 10min) | MTT | [183] |
| (ICG + S)@mSiO2 | PDT, Immunotherapy | H22 | 1 | 24 h([ICG] = 0.012 mg mL−1, [Sorafenib] = 0.08 mg mL−1 S or [(ICG + S)@mSiO2] = 0.1 mg mL−1) | MTT | [184] |
| NanoMnSor | Immunotherapy | JHH-7 | ≈30 | 72 h([sorafenib] = 4 μM,[MnO2] = 40 μM, hypoxic = 1% O2) | MTT | [179] |
| SEHPA | Gene therapy | Huh-7 | ≈25 | 24 h([sorafenib] = 8 μg/mL) | MTT | [185] |
| SF-PL/siGPC3 | Gene therapy | Hep-G2 | 36.6 | 48 h([sorafenib] = 4 μM) | CCK8 | [186] |
| EPC | Plant Extracts | BxPC-3 | ≈5 | 20 h([EPC] = 25 μM) | MTT | [187] |
| EB@QSSQ | Plant Extracts | A549 | 50 | 48 h([EB@QSSQ] = 4.1 × 10−6M) | MTT | [188] |